The prevalence of high-risk HPV infection is higher in the Asian region compared with that in Europe and the Northern American regions, suggesting that anti-VEGF agents may have a more pronounced effect among Asian patients with cervical cancer. The gene discussed is VEGFA; the disease is cervical cancer.